CardioDx Raises $45 Million

CardioDx, a Palo Alto, Calif.-based provider of cardiovascular genomic diagnostics, has raised $5 million in Series D funding from the GE Healthymagination Fund. The investment is part of a larger round, which a regulatory filing suggests could be worth upwards of $45.5 million ($34.5m sold so far). Other shareholders include Kleiner Perkins Caufield & Byers, TPG Biotech, Intel Capital, MDV, DAG Ventures, Pappas Ventures and Asset Management Group.

North AmericaUSBriefs